Bones are categorized as the second most prevalent location of extra-hepatic metastasis in Hepatocellular Carcinoma (HCC), which is linked to an extremely poor prognosis due to limited therapeutic options. N-methyladenosine (mA) is a prominent modification involved in HCC, but the exact mechanisms on how mA modifications induce HCC bone metastases (BM) remain unclear. The key modulators responsible for the abundant mA RNA modification-induced HCC BM was found to be the and . The expression of Anillin actin-binding protein () was dramatically higher in HCC with BM tissues, and its messenger RNA (mRNA) stability was enhanced via mA epitranscriptomic regulation by and . High and expression along with nuclear protein was clinically correlated with BM in HCC patients. Furthermore, HCC BM was attributed to over-expression of nuclear forming a transcriptional complex with which enhanced transcriptional activity to activate the mTORC1 pathway, therefore increased the expression of and disproportionated expression in bone microenvironment leading to malignant neoplasms invade bone tissue. In addition, inhibition of mA modification by DZNeP attenuated HCC BM. This data provides meaningful understanding of the modulation and association of mA epitranscriptomic-regulated BM in HCC, and moreover, defines potentially valuable therapeutic targets.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008695 | PMC |
| http://dx.doi.org/10.7150/ijbs.73570 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perioperative infections as a prognostic risk factor in hepatocellular carcinoma and cholangiocellular carcinoma: a comparative analysis.
World J Surg Oncol
January 2025
Department for General, Visceral and Pediatric Surgery, Medical Faculty, Heinrich Heine University Düsseldorf, University Hospital Düsseldorf, Düsseldorf, Germany.
Background: Hepatocellular Carcinoma (HCC) and cholangiocellular adenocarcinoma (CCA) are the most common primary liver tumors representing a major global health burden. In early disease stages, tumor resection may provide long-term survival in selected patients. However, morbidity and mortality rates are still relatively high after extended liver surgery with perioperative bacterial infections representing major complications.
View Article and Find Full Text PDFUtilizing liquid-liquid biopolymer regulators to predict the prognosis and drug sensitivity of hepatocellular carcinoma.
Biol Direct
January 2025
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China.
Background: Liquid-liquid phase separation (LLPS) is essential for the formation of membraneless organelles and significantly influences cellular compartmentalization, chromatin remodeling, and gene regulation. Previous research has highlighted the critical function of liquid-liquid biopolymers in the development of hepatocellular carcinoma (HCC).
Methods: This study conducted a comprehensive review of 3,685 liquid-liquid biopolymer regulators, leading to the development of a LLPS related Prognostic Risk Score (LPRS) for HCC through bootstrap-based univariate Cox, Random Survival Forest (RSF), and LASSO analyses.
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.
J Gastroenterol Hepatol
January 2025
Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Aim: This study aimed to compare the prognostic performance of the risk models for patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atez/Bev) as first-line treatment.
Methods: Among 449 patients included in this retrospective multicenter study, we compared the prognostic performance of 13 risk models for the 12-month and 18-month survival status using area under the curve (AUC), net reclassification improvement (NRI), and relative integrated discrimination improvement (IDI) analysis. We also constructed a calibration plot to assess the fitness of each model.
NPC1 controls TGFBR1 stability in a cholesterol transport-independent manner and promotes hepatocellular carcinoma progression.
Nat Commun
January 2025
State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, China.
Niemann-Pick disease type C protein 1 (NPC1), classically associated with cholesterol transport and viral entry, has an emerging role in cancer biology. Here, we demonstrate that knockout of Npc1 in hepatocytes attenuates hepatocellular carcinoma (HCC) progression in both DEN (diethylnitrosamine)-CCl induced and MYC-driven HCC mouse models. Mechanistically, NPC1 significantly promotes HCC progression by modulating the TGF-β pathway, independent of its traditional role in cholesterol transport.
View Article and Find Full Text PDFHigh SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease.
Clin Mol Hepatol
January 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Background/aims: There are no hepatocellular carcinoma (HCC) surveillance recommendations for non-viral chronic liver diseases (CLD), such as metabolic dysfunction associated steatotic liver disease (MASLD). We explored the Steatosis-Associated Fibrosis Estimator (SAFE) score to predict HCC in MASLD and other CLD etiologies.
Methods: Patients with various CLDs were included from medical centers in Taiwan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!